BACKGROUND: Hyperlipidimic mice administered angiotensin II have been used for the study of abdominal aortic aneurysms (AAAs). The purpose of this study was to examine the use of MRI for studying AAA development and for examining the effects of pharmacological intervention on AAA development in the apolipoprotein E-deficient mouse. METHODS AND RESULTS: Suprarenal aortic aneurysms were generated in apolipoprotein E-deficient mice administered angiotensin II (1000 ng/kg per min) for up to 28 days. In vivo MRI was performed serially (once weekly) to assess AAA development and rupture. Comparison of AAA size as measured by in vivo and ex vivo MRI resulted in excellent agreement (r=0.96, P<0.0001). In addition, MRI correlated with histology-derived AAA area assessment (in vivo versus histology: r=0.84, P<0.0001; ex vivo versus histology: r=0.89, P<0.0001). In a separate study, angiotensin II-administered apolipoprotein E-deficient mice were treated with doxycycline (broad-based matrix metalloproteinase inhibitor; 30 mg/kg per day for 28 days). MRI was able to noninvasively assess a reduced rate of AAA development (46% versus 71%, P<0.05), a decreased AAA area (2.56 versus 4.02 mm(2), P<0.01), and decreased incidence of rupture (43% versus 100%) in treated versus control animals. Inhibition of aorta matrix metalloproteinase 2/9 activity was observed in the treated animals. CONCLUSIONS: These results demonstrate the use of MRI to noninvasively and temporally assess AAA development on pharmacological intervention in this preclinical cardiovascular disease model.
BACKGROUND: Hyperlipidimic mice administered angiotensin II have been used for the study of abdominal aortic aneurysms (AAAs). The purpose of this study was to examine the use of MRI for studying AAA development and for examining the effects of pharmacological intervention on AAA development in the apolipoprotein E-deficientmouse. METHODS AND RESULTS: Suprarenal aortic aneurysms were generated in apolipoprotein E-deficientmice administered angiotensin II (1000 ng/kg per min) for up to 28 days. In vivo MRI was performed serially (once weekly) to assess AAA development and rupture. Comparison of AAA size as measured by in vivo and ex vivo MRI resulted in excellent agreement (r=0.96, P<0.0001). In addition, MRI correlated with histology-derived AAA area assessment (in vivo versus histology: r=0.84, P<0.0001; ex vivo versus histology: r=0.89, P<0.0001). In a separate study, angiotensin II-administered apolipoprotein E-deficientmice were treated with doxycycline (broad-based matrix metalloproteinase inhibitor; 30 mg/kg per day for 28 days). MRI was able to noninvasively assess a reduced rate of AAA development (46% versus 71%, P<0.05), a decreased AAA area (2.56 versus 4.02 mm(2), P<0.01), and decreased incidence of rupture (43% versus 100%) in treated versus control animals. Inhibition of aorta matrix metalloproteinase 2/9 activity was observed in the treated animals. CONCLUSIONS: These results demonstrate the use of MRI to noninvasively and temporally assess AAA development on pharmacological intervention in this preclinical cardiovascular disease model.
Authors: Craig J Goergen; Junya Azuma; Kyla N Barr; Lars Magdefessel; Dara Y Kallop; Alvin Gogineni; Amarjeet Grewall; Robby M Weimer; Andrew J Connolly; Ronald L Dalman; Charles A Taylor; Philip S Tsao; Joan M Greve Journal: Arterioscler Thromb Vasc Biol Date: 2010-11-11 Impact factor: 8.311
Authors: Nancy R Webb; Maria C De Beer; Joanne M Wroblewski; Ailing Ji; William Bailey; Preetha Shridas; Richard J Charnigo; Victoria P Noffsinger; Jassir Witta; Deborah A Howatt; Anju Balakrishnan; Debra L Rateri; Alan Daugherty; Frederick C De Beer Journal: Arterioscler Thromb Vasc Biol Date: 2015-03-05 Impact factor: 8.311
Authors: Ahmed Klink; Joeri Heynens; Beatriz Herranz; Mark E Lobatto; Teresa Arias; Honorius M H F Sanders; Gustav J Strijkers; Maarten Merkx; Klaas Nicolay; Valentin Fuster; Alain Tedgui; Ziad Mallat; Willem J M Mulder; Zahi A Fayad Journal: J Am Coll Cardiol Date: 2011-12-06 Impact factor: 24.094
Authors: Craig J Goergen; Kyla N Barr; Diem T Huynh; Jeffrey R Eastham-Anderson; Gilwoo Choi; Maj Hedehus; Ronald L Dalman; Andrew J Connolly; Charles A Taylor; Philip S Tsao; Joan M Greve Journal: J Magn Reson Imaging Date: 2010-10 Impact factor: 4.813
Authors: Evan H Phillips; Paolo Di Achille; Matthew R Bersi; Jay D Humphrey; Craig J Goergen Journal: IEEE Trans Med Imaging Date: 2017-02-06 Impact factor: 10.048
Authors: Xiaojie Xie; Hong Lu; Jessica J Moorleghen; Deborah A Howatt; Debra L Rateri; Lisa A Cassis; Alan Daugherty Journal: PLoS One Date: 2012-09-27 Impact factor: 3.752